Trial Profile
A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Gastrointestinal cancer; Large cell carcinoma; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms NIPINEC
- 06 Mar 2024 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 09 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Jul 2018 New trial record